180 results on '"D'Incà R"'
Search Results
2. A method to determine arc position in ICRF systems
3. Effects of live yeast supplementation to gestation and lactation diets on reproductive performance, immunological parameters and milk composition in sows
4. Optical signature of RF arcs in the ICRH frequency range
5. Progress in the design of a Sub-Harmonic Arc Detector for ITER
6. Intrauterine growth restriction reduces intestinal structure and modifies the response to colostrum in preterm and term piglets
7. Characterization of arcs in ICRF transmission lines
8. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice
9. Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre
10. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study
11. P.07.33 MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE MIMICKING PREBIOTIC ACTIVITY AND PROVING EFFECTS ON THE TREATMENT OF THE DISEASE
12. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment
13. Transcriptional downregulation of tight junction protein ZO-1 in active coeliac disease is reversed after a gluten-free diet
14. Frequency of NOD 2/CARD 15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study
15. T.06.7 INCIDENT COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE
16. AF.56 COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
17. AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
18. Effect of zinc supplementation on trace elements and intestinal metallothionein concentrations in experimental colitis in the rat
19. Clinical features in familial cases of Crohn’s disease and ulcerative colitis in Italy: a GISC study
20. T06.02.15 LOW PREVALENCE OF COLORECTAL NEOPLASIA IN MICROSCOPIC COLITIS: A PROSPECTIVE, MULTICENTER STUDY
21. T04.02.8 INFLIXIMAB ORIGINATOR, INFLIXIMAB BIOSIMILAR AND ADALIMUMAB ARE EQUALLY EFFECTIVE AND SAFE IN ULCERATIVE COLITIS AND CROHN'S DISEASE – A REAL-LIFE COHORT STUDY
22. T04.01.21 INTESTINAL MICROBIOTA CHANGES ACCORDING TO DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
23. T04.02.9 THE EFFECTIVENESS OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE IN DIFFERENT REAL-WORD SCENARIOS
24. T04.01.3 REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY
25. T02.02.2 INFLAMMATORY BOWEL DISEASES AND CELIAC DISEASE PATIENTS' NUTRITIONAL KNOWLEDGE
26. OC.12.6 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
27. MALDI-TOF/MS peptidomic profiling for the diagnosis of inflammatory bowel diseases
28. P.07.8 MAGNETIZATION TRANSFER IMAGING FOR THE ASSESSMENT OF INTESTINAL FIBROSIS IN CROHN'S DISEASE
29. P.07.32 THE QUALITY OF SLEEP IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS IMPAIRED INDEPENDENTLY FROM THE DISEASE ACTIVITY STATUS – A CROSS-SECTIONAL STUDY
30. P.07.28 PREVIOUS EXPOSURE TO INFLIXIMAB INDUCES CROSS-REACTIVITY AND AFFECTS ADALIMUMAB TROUGH LEVELS: DATA FROM A PROSPECTIVE, MULTICENTRE STUDY
31. P.07.17 EFFICACY AND SAFETY OF VEDOLIZUMAB IN REAL LIFE: EXPERIENCE IN A TERTIARY REFERRAL CENTRE
32. P.07.20 EFFECTIVENESS OF VEDOLIZUMAB IN CLINICAL REMISSION PATIENTS: UNRAVELLING THE GREY ZONE IN REAL LIFE PRACTICE
33. P.07.2 DISEASE ACTIVITY INFLUENCES DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – A CROSS-SECTIONAL STUDY
34. P.01.34 CLEAR CELL RENAL CARCINOMA GASTRIC METASTASIS PRESENTING WITH GASTROINTESTINAL BLEEDING: A CASE REPORT
35. OC.13.5 TERMINAL ILEUM ILEOSCOPY AND HISTOLOGY IN PATIENTS UNDERGOING HIGH-DEFINITION COLONOSCOPY WITH VIRTUAL CHROMOENDOSCOPY FOR CHRONIC NON-BLOODY DIARRHEA: A PROSPECTIVE MULTI-CENTER STUDY
36. OC.12.4 RAPID POINT-OF-CARE MONITORING OF ANTI-INFLIXIMAB ANTIBODIES AND CLINICAL SCORES IN INFLAMMATORY BOWEL DISEASE PATIENTS
37. OC.09.6 PERFORATING CROHN'S DISEASE AND EXTENSIVE COLITIS AS RISK FACTORS FOR INCIDENT CANCER: A MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 6 YEARS
38. OC.09.3 INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH
39. PC.01.4 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
40. P.07.26 QUALITY OF LIFE ASSESSMENT IN ULCERATIVE COLITIS OUTPATIENTS: A CROSS SECTIONAL STUDY
41. P.07.3 EFFECTIVENESS OF GOLIMUMAB IN REAL LIFE – A SINGLE CENTER PROSPECTIVE STUDY
42. P.07.2 OUTCOME IN ULCERATIVE COLITIS AFTER SWITCH FROM SUBCUTANEOUS ANTI-TNF TO INTRAVENOUS ANTI-TNF: A MULTICENTRE STUDY
43. P.02.24 EVALUATION OF QUALITY OF LIFE IN IBD PATIENTS TREATED WITH ANTI-TNFA THERAPY
44. P.02.12 MICROBIOTA PROFILE AND DYSBIOSIS ASSESSMENT IN CLINICAL PRACTICE: A PILOT STUDY ON IBD PATIENTS
45. P.02.7 MMP3 (METALLOPROTEINASE 3): A NEW MARKER FOR ASSESSING LOSS OF RESPONSE TO INFLIXIMAB IN IBD
46. OC.16.5 IMPACT OF ADALIMUMAB'S PATIENT SUPPORT PROGRAM ON ADHERENCE TO ANTI-TNF-ALFA THERAPY IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER ANALYSIS
47. OC.11.1 PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) EXPRESSION IS COUPLED WITH MICROSATELLITE INSTABILITY IN NON-FAMILIAL SMALL BOWEL CARCINOMAS ASSOCIATED OR NOT WITH COELIAC DISEASE OR CROHN'S DISEASE: RESULTS FROM THE SMALL BOWEL CANCER ITALIAN CONSORTIUM
48. OC.12.3 INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY
49. OC.02.5 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART1
50. OC.10.4: Survival of Non-Familial Small Bowel Carcinomas Depends on the Underlying Intestinal Immune-Mediated Disorder
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.